symptoms is mediated by tryptophan (TRP) degradation along the kynurenine (KYN) pathway. Methods: The data are part of an observational, prospective cohort study in five urban dialysis centres in The Netherlands. Depressive symptoms were determined with the Beck Depression Inventory. Peripheral blood was collected before dialysis to measure inflammatory markers [high sensitivity Creactive protein (HsCRP), interleukin (IL)-1b, IL-6, IL-10 and tumour necrosis factor-a (TNF-a)], TRP, KYN and 3-hydroxykynurenine. The KYN/TRP ratio was used as a measure of TRP degradation. The association between inflammatory markers and depressive symptoms was determined using linear regression analysis and adjusted for the KYN/TRP ratio.
Results: In total, 490 chronic dialysis patients were included. HsCRP [b¼ 3.8; confidence interval (CI): 1.0-6.6], IL-6 (b¼ 9.1; CI: 4.0-14.1) and TNF-a (b¼ 1.3; CI: 0.9-1.7) were associated with the KYN/TRP ratio. We found significant associations between HsCRP (b¼ 0.8; CI: 0.3-1.3) and IL-6 (b¼ 1.2; CI: 0.3-2.2) levels and depressive symptoms. However, this association was not attenuated after adjustment for the KYN/TRP ratio. Also, no significant associations were found between the KYN/TRP ratio and depressive symptoms.
Conclusion:
The association between inflammatory markers and depressive symptoms in chronic dialysis patients was not mediated by TRP degradation along the KYN pathway.
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I N T R O D U C T I O N
Depressive symptoms are common among chronic dialysis patients [1] and are strongly associated with morbidity [2] and both short-and long-term mortality [3] . Inflammatory markers are increased in dialysis patients [4, 5] , and multiple studies have found associations between high-inflammatory markers [especially interleukin (IL)-6] and depressive symptoms [6] . Various studies have proposed that inflammation and depressive symptoms might be linked by enhanced tryptophan (TRP) degradation along the kynurenine (KYN) pathway catalysed by the inducible enzyme indoleamine 2,3-dioxygenase (IDO) [7] [8] [9] [10] . Inflammatory markers activate IDO, which degrades TRP into KYN [11, 12] (Figure 1 ). TRP is a precursor of the neurotransmitter serotonine (5-HT), and TRP degradation by IDO causes reduced TRP availability to synthesize 5-HT [13] . Low concentrations of 5-HT in the central nervous system cause depressive symptoms [14, 15] . Also, the development of depressive symptoms is influenced by degradation products of KYN, in particular quinolinic acid (QA) and 3-hydroxykynurenine (3-OH-KYN) [12] . Besides TRP degradation by IDO, TRP is also degraded into KYN by the liver enzyme tryptophan 2,3-dioxygenase (TDO), which is activated by glucocorticoids [12] including the stress hormone cortisol.
Evidence for the role of IDO activity in the development of depressive symptoms came from theory [11, 16] , animal studies [17, 18] and from patients on interferon a therapy [19, 20] , which subsequently caused depression. However, despite this evidence, a recent study in depressed patients did not find indications for TRP degradation, mediating the association between pro-inflammatory markers and depression [21] . A possible explanation is that this association can only be found in defined groups of depressed patients with high levels of inflammation. A patient population that is known not only for high levels of inflammation [4, 5] , but also for low TRP levels [22] and high KYN metabolites [23] is the population of dialysis patients. Therefore, the dialysis patient group seems the appropriate population in which to examine the role of TRP degradation in the association between inflammatory markers and depressive symptoms.
To the best of our knowledge, no previous studies have examined the mechanism linking the association between inflammatory markers and depressive symptoms in dialysis patients. Understanding of the role of inflammation in the development of depressive symptoms among dialysis patients is important for developing appropriate therapy or for preventing the development of depressive symptoms. Therefore, we aimed to examine whether the association between inflammatory markers and depressive symptoms in chronic dialysis patients is mediated by TRP degradation along the KYN pathway.
M A T E R I A L S A N D M E T H O D S

Study design
Data were collected as part of an observational, prospective cohort study, the DIVERS study (Depression related factors and outcomes In dialysis patients with Various Ethnicities and Races Study). Both prevalent and incident chronic dialysis patients were included from four urban teaching hospitals and one university hospital in the Netherlands.
Prevalent and incident dialysis patients were included between June 2012 and December 2013 and between June 2012 and December 2014, respectively. Patients were approached for study participation during dialysis treatment or during an outpatient appointment. Inclusion criteria were as follows: age !18 years and dialysis treatment, either haemodialysis (both haemodialysis and haemodiafiltration) or peritoneal dialysis, for at least 90 days. Exclusion criteria were the presence of cognitive impairments (e.g. dementia) or inability to complete a questionnaire in Dutch, English, Turkish or Moroccan Arabic due to a language barrier. The baseline assessment consisted of a blood sample, which was drawn before dialysis in haemodialysis patients and during a visit to the outpatient clinic in peritoneal dialysis patients, and completion of a questionnaire. For the current analysis, patients were included in case of complete data on inflammatory markers [high sensitivity C-reactive protein (HsCRP), IL-1b, IL-6, IL-10, tumour necrosis factor-a (TNFa)] and tryptophan degradation (TRP, KYN and 3-OH-KYN), and if they had returned the questionnaires. In total, 548 chronic dialysis patients were included in the DIVERS study from June 2012 to December 2014. Of these patients, 41 had no measurement of inflammatory markers at baseline. Seventeen
other patients did not return their questionnaire. Therefore, we excluded these 58 patients, leaving 490 (89%) participating patients.
All patients gave written informed consent before inclusion. The DIVERS study was approved by the medical ethical committees of all participating centres. This study was carried out in accordance with the Helsinki declaration of 1975, as revised in 2008.
Socio-demographic and clinical characteristics
The following socio-demographic characteristics were collected through a questionnaire: marital status, having children (yes/no), educational level, employment (yes/no), smoking (yes/no) and alcohol use (yes/no).
We collected the following data from electronic medical records: age, gender, dialysis modality, dialysis vintage, body mass index (BMI), primary kidney disease, comorbidities, antidepressant use (yes/no) and residual diuresis. Primary kidney disease was classified according to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) codes [24] and grouped into four categories: diabetes mellitus, glomerulonephritis, renal vascular disease and other. Level of comorbidities was determined using the Davies comorbidity index, indicating no, intermediate or severe comorbidity [25] . Residual diuresis indicates remaining glomerular filtration rate and was defined as a urine production of >100 mL per day.
Depressive symptoms
Depressive symptoms were measured with the Beck Depression Inventory (BDI) [26] . The BDI consists of 21 questions, which are scored on a 0-3 scale. Summed scores range from 0 to 63. In a validation study performed in the ESRD group of one of the centres that participated in this study [27] , a sensitivity of 0.75 and a specificity of 0.90 for the detection of depression were found when a cut-off point of 13 was used.
Therefore, we used the cut-off point of 13 for the presence of depression in Table 1 .
Inflammatory markers
Peripheral blood was collected in anti-coagulant-free EDTA tubes before dialysis in haemodialysis patients and during an outpatient visit in peritoneal dialysis patients. All samples were immediately centrifuged (at 1200 g for 10 min), and serum was stored in aliquots at À80 C until analysis. Pro-inflammatory markers (HsCRP, IL-1b, IL-6 and TNF-a) and antiinflammatory marker IL-10 were assessed by the Department of Rheumatology and Clinical Immunology (University Medical Centre Groningen, Groningen, The Netherlands) using the Magnetic Luminex Screening or Performance assay (R&D Systems, Abingdon, UK) according to the manufacturer's instructions. Samples were measured using Luminex 100 System (Luminex, Austin, TX, USA), and data were analysed with StarStation software, version 2.3 (AppliedCytometry, Birmingham, UK).
TRP and KYN
Concentrations of TRP and its metabolites KYN and 3-OH-KYN were measured by the University Medical Centre Groningen, The Netherlands (Department of Laboratory Medicine), using an automated online solid-phase extractionliquid chromatographic-tandem mass spectrometric (XLC-MS-MS) method with deuterated internal standards, using described methods [28] . We determined IDO activity (TRP degradation) by calculating the KYN/TRP ratio Â10 3 (KYN/TRP ratio).
Statistical analysis
Baseline characteristics are presented for the total study population and stratified for patients with and without depression. Continuous data are expressed as mean (with standard deviation) or median [with interquartile range (IQR)] depending on the distribution. Categorical data are presented as percentages. A t-test or Mann-Whitney U-test was used to compare Because of a skewed distribution, HsCRP, IL-1b, IL-6 and IL-10 levels were log transformed. This transformation led to a normal distribution.
We first examined the association between inflammatory markers and KYN/TRP ratio using univariate and multivariate linear regression. We adjusted for age, gender, education, smoking, alcohol use and BMI, based on the previous literature [21] . Second, we examined the association between inflammatory markers and depressive symptoms using univariate linear regression. Subsequently, we adjusted this association for the KYN/TRP ratio to examine whether the association between inflammatory markers and depressive symptoms was mediated by TRP degradation. In this analysis, we also adjusted for age, gender, education, smoking, alcohol use, BMI, dialysis modality, cause of renal failure, comorbidities, residual diuresis and dialysis vintage. Third, we examined the association between TRP, 3-OH-KYN and KYN/TRP ratio and depressive symptoms, as both TRP and degradation products of kynurenine (3-OH-KYN) could be related to depressive symptoms. We performed this linear regression unadjusted and adjusted for age, gender, education, smoking, alcohol use, BMI, dialysis modality, cause of renal failure, comorbidities, residual diuresis and dialysis vintage.
The average percentage of missing data was 2.2% on the socio-demographic variables, 1.5% on clinical variables and 3.9% on the BDI. To create complete datasets for multivariate regression analysis, missing socio-demographic and clinical data and missing values on the BDI were imputed with standard multiple imputation techniques in SPSS (using 10 repetitions) [29] . These techniques predict missing values using the patient's available characteristics. Dialysis vintage in months was first square-root transformed before entering the imputation model, because of a skewed distribution.
All statistical analyses were performed with SPSS statistical software, version 21. P-values <0.05 were considered statistically significant.
Sensitivity analyses
To test the robustness of our results, we performed several sensitivity analyses. First, we also adjusted the association between inflammatory markers and depressive symptoms for TRP, KYN and 3-OH-KYN separately. Next, we adjusted for a combination of these variables (TRP and KYN; TRP and 3-OH- and for the ratio 3-OH-KYN/TRP. Second, we examined whether TRP degradation mediates the association between inflammatory markers and cytokines in a subgroup of patients with severe depressive symptoms, namely with a BDI score of 25 and higher, and we stratified our analysis by BDI tertiles. Third, we analysed haemodialysis patients and peritoneal dialysis patients separately to identify a possible treatment effect, and we stratified further for haemodialysis and haemodiafiltration patients. Finally, we performed a complete case analysis, and we performed an analysis in which we also imputed unreturned questionnaires of patients, which were therefore imputed based on available data collected from electronic medical records.
R E S U L T S
Patient sample
Baseline characteristics of the 490 included chronic dialysis patients are shown in Table 1 . Among patients with depression, a significantly higher number had a lower educational level, more were unemployed, fewer were incident patients and more had a longer dialysis vintage. HsCRP was significantly higher in the patients with depression (3.0; IQR: 0.7-7.4) than in the patients without depression (1.7; IQR: 0.6-6.4). IL-10 was significantly lower in the patients with depression (0.28; IQR: 0.13-0.61) than in the patients without depression (0.41; IQR: 0.2-0.7). Table 2 shows the associations between inflammatory markers and KYN/TRP ratio. Among the total patient group HsCRP [b¼ 3.8; confidence interval (CI): 1.0-6.6], IL-6 (b¼ 9.1; CI: 4.0-14.1) and TNF-a (b¼ 1.3; CI: 0.9-1.7) were associated with the KYN/TRP ratio. These associations remained similar after full adjustment. No significant associations were found between IL-1b and KYN/TRP ratio, or between IL-10 and KYN/TRP ratio. Table 3 shows the associations between inflammatory markers and depressive symptoms. Univariate linear regression showed that HsCRP (b¼ 0.8; CI: 0.3-1.3) and IL-6 (b¼ 1.2; CI: 0.3-2.2) were significantly associated with depressive symptoms. To examine whether TRP degradation explains part of these associations, we adjusted for the KYN/TRP ratio. This adjustment did not attenuate the association between HsCRP and depressive symptoms, or between IL-6 and depressive symptoms. The associations remained equally strong after adjustment for socio-demographics, lifestyle factors and medical variables.
Associations between inflammatory markers and TRP degradation
Associations between inflammatory markers and depressive symptoms
Associations between TRP, and TRP degradation and depressive symptoms Table 4 shows the associations between TRP, 3-OH-KYN and the KYN/TRP ratio and depressive symptoms. We found a significant association between plasma TRP levels and depressive symptoms (b¼ À0.1; CI: À0.2 to À0.01). This association was no longer significant after adjustment for sociodemographics, lifestyle factors and medical variables. We also found no significant association between KYN/TRP ratio and depressive symptoms, or between 3-OH-KYN and depressive symptoms.
Sensitivity analysis (data not shown)
Adjustment for TRP, KYN and 3-OH-KYN separately did not attenuate the associations between inflammatory markers and depressive symptoms, nor were these associations affected by adjustment for the combination of these variables and the 3-OH-KYN/TRP ratio. Associations between inflammatory markers and depressive symptoms were stronger, but not significant in the subgroup of patients with severe depressive symptoms (N ¼ 86) compared with the total patient group. In the group of patients in the highest tertile of the BDI, we found stronger associations between inflammatory markers and depressive symptoms than in patients in the lowest and middle tertiles, but none of the associations was significant. Adjustment for KYN/TRP did not attenuate these associations.
Among haemodialysis patients (N ¼ 384), we found similar results as in the total patient group. The peritoneal dialysis patient group (N ¼ 52) and the haemodiafiltration patient group (N ¼ 54) were too small to draw conclusions.
In the complete case analysis, we found exactly the same associations between cytokines and depressive symptoms as in the imputed dataset, and adjustment for the KYN/TRP ratio did not attenuate this association. When we also imputed 17 unreturned questionnaires, the association between IL-6 and depressive symptoms was not significant but did not change after adjustment for the KYN/TRP ratio.
D I S C U S S I O N
This study is the first to examine whether IDO/TDO-mediated TRP degradation explains the association between inflammatory markers and depressive symptoms in chronic dialysis patients. We found significant associations between the inflammatory markers HsCRP and IL-6 and depressive symptoms, but we found no evidence that this association is mediated by TRP degradation along the KYN pathway.
The associations between inflammatory markers and depressive symptoms have been studied extensively in chronic dialysis patients (reviewed by Taraz et al. [6] ). However, results are inconsistent: various pro-inflammatory cytokines were found to be associated with depression, whereas in other studies no significant associations were found. The most consistent associations have been found between IL-6 and depressive symptoms [6] . The reasons for these different findings are unclear but may include different methods for the assessment of depressive symptoms and different techniques for the analysis of plasma cytokine levels [9] .
We could not confirm the role of IDO activation in the association between inflammatory markers and depressive symptoms in chronic dialysis patients. A similar approach was used by a cohort study consisting of almost 3000 subjects with a current or lifetime diagnosis of depression or at risk to develop a depression [21] , which came to the same conclusion. Nevertheless, there is evidence for a role of TRP degradation in the pathophysiology of depression from patient studies. In patients treated with interferon a, which is known to induce IDO, an increase in depressive symptoms and TRP degradation was found [19, 20] . Possibly, interferon a is a stronger IDO inducer than mild inflammation. Other patient studies examined the direct association between KYN/TRP ratio and depression, without measuring inflammatory markers [30] [31] [32] . These studies found higher KYN/TRP ratios to be associated with a higher depression score among patients with coronary artery disease [32] and among patients with HIV infection [31] , while a study among patients with Irritable Bowel Syndrome [30] did not find a correlation between the KYN/TRP ratio and the severity of depressive symptoms. We also examined this direct association, but found no significant association with depressive symptoms. Another proposed mechanism between inflammatory markers and depressive symptoms is pro-inflammatory cytokine-induced hyperactivity of the hypothalamic-pituitaryadrenal axis [33, 34] , by causing impaired glucocorticoidmediated feedback.
The mean TRP concentration found in this study was much lower (27.5 mmol/L) than TRP levels in the general population (63.9 mmol/L) [21] . Dialysis patients also have significantly elevated plasma concentrations of KYN (4.6 versus 1.8 mmol/L) [23] . The TRP concentration in dialysis patients without depression in our study was also much lower than in healthy subjects in the general population, and the KYN concentration was higher [21] . Both the low TRP concentration and elevated KYN metabolites may explain the high prevalence of depression among dialysis patients. So far, no other studies in dialysis patients have examined the association of TRP and KYN metabolites with depressive symptoms/depression, but two studies examined the association between TRP levels and quality of life [22, 35] . They found a significant correlation between lower TRP levels and decline in quality of life, without adjustments made for confounders. We also found a significant association between lower TRP and more depressive symptoms, but after adjustment for socio-demographics, lifestyle factors and medical variables this association lost its significance (P ¼ 0.07). These results are similar to those in non-somatic compromised depressed patients [36] and may provide specific targets for treating depression in dialysis patients. For example, it is assumed that selective serotonin-reuptake inhibitors could be more effective in treating depressive symptoms in patients with low TRP levels [22] .
Some limitations of this study should be noted. First, we did not obtain the diagnosis of depression by means of structured interviews. It may be possible that the reason why we could not detect an association between TRP degradation and depressive symptoms is that this association is only present in the case of the diagnosis depression. However, Quak et al. [21] used a structured interview and also could not confirm this association. Notably, the analysis of the subgroup of patients with the highest score on the BDI (>25) did also not reveal an association between TRP degradation and depressive symptoms. Second, we measured IDO activity by calculating the KYN/TRP ratio instead of measuring the IDO enzyme itself. The KYN/TRP ratio does not distinguish IDO activity from TDO activity, which may have influenced the results. Third, we measured TRP and KYN in peripheral blood, which may differ from the concentrations in the brain. Among dialysis patients, plasma concentrations of TRP and KYN may be influenced by residual renal clearance or dialysis. However, we adjusted our analysis for residual function. Finally, the cross-sectional design of the study did not allow us to draw conclusions regarding causality of the associations.
In conclusion, TRP degradation along the KYN pathway did not mediate the association between inflammatory markers and depressive symptoms in chronic dialysis patients. However, we did find associations between inflammatory markers and depressive symptoms and between inflammatory markers and TRP degradation. Future research should also examine other KYN pathway metabolites, as well as blood-brain barrier competing amino acids, and fluctuations over time in KYN and TRP, inflammatory markers and depressive symptoms in chronic dialysis patients.
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A B S T R A C T
Background: Erythropoiesis-stimulating agents (ESAs) are the cornerstone of the treatment for anemia in end-stage renal disease (ESRD) patients. Although a correlation has been established between ESAs and increased tumor growth among patients with cancer-related anemia, an association with a higher incidence of cancer among chronic dialysis patients remains relatively unclear.
Methods: We completed a nested case-control study in a cohort of 4574 patients who began chronic dialysis treatment between 1 January 2001 and 31 December 2007 in Quebec, Canada, utilizing dialysis registry and administrative databases exclusively to extract our data. We excluded patients with a prior diagnosis of cancer. Eligible cases were identified by the time of initial cancer diagnosis obtained from either the hospital's discharge or physician billing form. We then randomly selected up to 10 controls for each case. ESA exposure was evaluated between 6 and 9 months prior to the initial cancer diagnosis. The mean weekly exposure was used to categorize ESA usage as either a low dose (<30 mg/week), moderate dose (30-70 mg/week) or high dose (>70 mg/week). We estimated the association between ESAs and the risk of developing cancer using a multivariable conditional logistic regression. Keywords: cancer, chronic renal dialysis, epidemiology, EPO, erythropoiesis-stimulating agents
I N T R O D U C T I O N
Erythropoiesis-stimulating agents (ESAs) have drastically changed the treatment of anemia among end-stage renal disease (ESRD) patients. More than half of ESRD patients suffer from anemia, enforcing the need for the use of ESAs to both reduce the need for blood transfusions and improve overall quality of life [1] . Despite these noted advantages, some studies have suggested that, among patients with cancer-related anemia, ESAs could further increase the risk of mortality [2] [3] [4] . 
